MedTrace Logo

Single Arm Clinical Trial (Gut Microbiota and HCC)

NCT06563947 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-08-21

No results posted yet for this study

Summary

To evaluate the efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced HCC who have progressed after treating with immune checkpoint inhibitors in combination with anti-angiogenesis targeted agents.

Conditions

Interventions

BIOLOGICAL

Oral enterobacterium capsules

Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.

Sponsors & Collaborators

  • Nanjing Xiershou Biotechnology Co., Ltd

    collaborator UNKNOWN

  • Xu Yong, MD

    lead OTHER

Principal Investigators

  • Yong Xu, Dr · Secretary of the Party Committee of the Shenzhen Third People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-24
Primary Completion
2026-05-20
Completion
2026-11-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06563947 on ClinicalTrials.gov